Publication of Standalone Un-Audited Financial Results for Second Quarter and Half Year Ended on September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals has published its unaudited standalone financial results for the second quarter and first half of FY26 (ended September 30, 2025) in Business Standard (English) and Jai Hind (Gujarati), as required by SEBI's Listing Regulations. For Q2 FY26, total income from operations stood at around ₹750 lakhs versus ₹657 lakhs in Q2 FY25, showing roughly 14% year-on-year growth. For the half year, total income rose to about ₹1,409 lakhs compared to ₹1,047 lakhs in H1 FY25, a jump of around 35%. Net profit before tax for H1 FY26 was around ₹157 lakhs, slightly lower than ₹167 lakhs in the same period last year, while the company reported a small after-tax profit of about ₹23.78 lakhs for Q2 FY26. The full detailed results have been filed with BSE and are available on the company's website.
Revenue growth is strong on both a quarterly and half-yearly basis, but margins and bottom-line profit have softened compared to the previous year, suggesting rising costs or one-off pressures. For shareholders, this is a routine compliance filing with mixed operational signals — top-line momentum is positive, though profitability trends will need watching.